Dr Alberta di Pasquale discusses the latest data from the TIDES trial on the immunogenicity, efficacy and safety profile of the TAK-003 dengue vaccine.
Learning outcomes
Upon completing this module, participants will be able to:
Understand the significant burden of dengue
Describe a comprehensive strategy for dengue management
List the characteristics and desired immune response profile of an effective dengue vaccine
Understand the composition of the TAK-003 vaccine
Gain insights on the immunogenicity, efficacy and safety of the TAK-003 vaccine